Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Granito

Showing results (121-130 of 136) with videos related to

Pageof 14
Sort By:
Plos One|May 8, 2020
The role of PNI to predict survival in advanced hepatocellular carcinoma treated with SorafenibFrancesco Caputo, Vincenzo Dadduzio, Francesco Tovoli, et al.
International Journal of Cancer|February 11, 2014
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 studyMario Scartozzi, Luca Faloppi, Gianluca Svegliati Baroni, et al.
Targeted Oncology|October 28, 2020
Correction to: Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular CarcinomaGiulia Orsi, Francesco Tovoli, Vincenzo Dadduzio, et al.
Targeted Oncology|October 12, 2020
Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular CarcinomaGiulia Orsi, Francesco Tovoli, Vincenzo Dadduzio, et al.
Liver Cancer|August 20, 2021
Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular CarcinomaFrancesco Tovoli, Vincenzo Dadduzio, Stefania De Lorenzo, et al.
Lancet (London, England)|December 10, 2016
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trialJordi Bruix, Shukui Qin, Philippe Merle, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 19, 2016
The evolutionary scenario of hepatocellular carcinoma in Italy: an updateLaura Bucci, Francesca Garuti, Barbara Lenzi, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 29, 2022
Potential feasibility of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma treated with tyrosine-kinase inhibitorsBenedetta Stefanini, Laura Bucci, Valentina Santi, et al.
European Journal of Gastroenterology & Hepatology|January 14, 2005
Antiendomysial and antihuman recombinant tissue transglutaminase antibodies in the diagnosis of coeliac disease: a biopsy-proven European multicentre studyPekka Collin, Katri Kaukinen, Harald Vogelsang, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|February 10, 2024
Sorafenib and Metronomic Capecitabine in Child-Pugh B patients with advanced HCC: A real-life comparison with best supportive careBenedetta Stefanini, Laura Bucci, Valentina Santi, et al.
Pageof 14

Showing results (121-130 of 136) with videos related to

Sort By:
Pageof 14
Plos One|May 8, 2020
The role of PNI to predict survival in advanced hepatocellular carcinoma treated with SorafenibFrancesco Caputo, Vincenzo Dadduzio, Francesco Tovoli, et al.
International Journal of Cancer|February 11, 2014
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 studyMario Scartozzi, Luca Faloppi, Gianluca Svegliati Baroni, et al.
Targeted Oncology|October 28, 2020
Correction to: Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular CarcinomaGiulia Orsi, Francesco Tovoli, Vincenzo Dadduzio, et al.
Targeted Oncology|October 12, 2020
Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular CarcinomaGiulia Orsi, Francesco Tovoli, Vincenzo Dadduzio, et al.
Liver Cancer|August 20, 2021
Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular CarcinomaFrancesco Tovoli, Vincenzo Dadduzio, Stefania De Lorenzo, et al.
Lancet (London, England)|December 10, 2016
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trialJordi Bruix, Shukui Qin, Philippe Merle, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 19, 2016
The evolutionary scenario of hepatocellular carcinoma in Italy: an updateLaura Bucci, Francesca Garuti, Barbara Lenzi, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 29, 2022
Potential feasibility of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma treated with tyrosine-kinase inhibitorsBenedetta Stefanini, Laura Bucci, Valentina Santi, et al.
European Journal of Gastroenterology & Hepatology|January 14, 2005
Antiendomysial and antihuman recombinant tissue transglutaminase antibodies in the diagnosis of coeliac disease: a biopsy-proven European multicentre studyPekka Collin, Katri Kaukinen, Harald Vogelsang, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|February 10, 2024
Sorafenib and Metronomic Capecitabine in Child-Pugh B patients with advanced HCC: A real-life comparison with best supportive careBenedetta Stefanini, Laura Bucci, Valentina Santi, et al.
Pageof 14